SARS-CoV-2 Antibody Diagnostic testing on the ZIVA platform
Cavidi is working to add a SARS-CoV-2 antibody serology test to our newly developed fully automated ZIVA system analyzer, a multi-assay platform scheduled for CE-IVD certification in Q3, 2020. ZIVA is an ultra-sensitive immuno-assay technology platform fully capable of adding new test assays, including SARS-CoV-2 antibody detection and monitoring.
ZIVA was designed to deliver cutting edge technology for mid-tier laboratories in Low and Middle Income Countries; very robust, easy to use, and fit for purpose. We have a system concept that allows us to add future immunoassay tests with simple software script and highly sensitive reagent kits optimized to run on ZIVA. We are currently developing a quantitative serological assay to detect IgM and IgG as well as neutralizing antibodies against SARS-CoV-2 to aid in detection of active infection as well as to identify previously infected individuals (see chart below). We are working with local Nordic partners who already have a rapid test for antigens and access to clinical samples from hospitals which will shorten development time.
Our value add would be to provide the ZIVA system with batch run, load and walk away simplicity, for up to 90 test results in a few hours.